Sartorius (SRT) Q4 2024 earnings summary

Executive summary

• Achieved revised 2024 guidance for revenue and profitability, with market recovery gaining momentum and strong Q4 performance; order intake up 10.8% in constant currencies.

• Underlying growth drivers are returning as temporary volatility subsides, especially in bioprocessing and advanced therapies.

• Profitability remains robust, supported by efficiency programs offsetting lower capacity utilization and inventory reduction.

• Lab Products & Services sales were slightly below prior year due to soft end markets, especially in China, but profitability remained robust.

Financial highlights

• Group sales revenue was €3.381 billion, flat year-over-year (+0.1% constant currency); order intake rose 10.8%.

• Underlying EBITDA margin at 28.0% (€945 million), hitting guidance midpoint; underlying EPS (ord.) was €4.05.

• Free cash flow doubled to €550 million, driven by working capital and CapEx discipline; operating cash flow increased 14.4% to €976 million.

• CapEx reduced to 12.1% of sales from 16.5% prior year.

• Equity ratio at 38.6%, aided by a Q1 capital increase; net debt reduced to €3.75 billion.

Outlook and guidance

• 2025 outlook is cautious: moderate, profitable growth expected above market, with margin expansion and continued deleveraging focus.

• Underlying EBITDA margin expected to expand slightly on moderate revenue growth; focus on organic debt reduction and investment management.

• Quantitative guidance to be issued with Q1 results in April; midterm targets unchanged.